This week

a dozen GH peptides got compounding access in April — GHRP-2 wasn't on the list

When the February 27, 2026 policy shift from HHS Secretary Robert F. Kennedy Jr. kicked off the peptide reclassification wave, the list of compounds that came off the FDA's Category 2 restricted list was long enough to generate weeks of wellness-industry headlines: BPC-157, thymosin alpha-1, ipamorelin, CJC-1295, AOD-9604, GHK-Cu, selank, semax, KPV, and MOTS-C all moved back to compounding-eligible status. A [June 4 Pharmacy Times analysis](https://www.pharmacytimes.com/view/the-peptide-reclassification-everyone-s-talking-about-a-pharmacist-s-take-on-what-rfk-jr-s-announcement-actually-means) laid out the full picture, and the column of compounds that did not make the cut includes GHRP-2 — still restricted alongside GHRP-6, Melanotan II, LL-37, and PEG-MGF. This week a fresh research publication appeared covering a modified GRF 1-29 plus GHRP-2 peptide blend and its somatotroph signaling profile, treating GHRP-2 as live investigational territory. The legal situation is quietly unchanged. The research community, and the wellness stack world, mostly did not notice.

The actual mechanism

GHRP-2 hits the ghrelin receptor — and the appetite system comes bundled with it

GHRP-2 is a synthetic hexapeptide that activates the ghrelin receptor — GHS-R1a — in a way that triggers growth hormone release from pituitary somatotroph cells. The intracellular signaling runs through at least two distinct pathways: the PKC-calcium axis and the cAMP-PKA axis, meaning the GH secretory signal engages redundancy that single-pathway GHRH stimulation does not. Unlike GHRH analogs like CJC-1295 or sermorelin, which work by amplifying the growth hormone releasing hormone signal upstream, GHRP-2 bypasses that step and hits the secretagogue receptor directly. Research has confirmed it can produce GH release even in models where the GHRH receptor is nonfunctional — a detail with clinical diagnostic significance. The receptor it activates is not limited to GH signaling. Ghrelin itself drives appetite, and GHRP-2 shares that property. Studies in healthy men document food intake increases of roughly 35% following GHRP-2 administration. GH release and appetite stimulation arrive through the same receptor, and that bundling is part of why the safety review for GHRP-2 does not look identical to the review for compounds that only touch the GHRH side of GH-axis pharmacology.

What the community says

the stack world is treating GHRP-2 like it cleared the April reset — it didn't

In online GH-axis peptide discussion, GHRP-2 is positioned almost universally as a secretagogue to pair with GHRH analogs — the synergistic stack that became dominant in research and optimization circles because combining GHS-R1a agonism with GHRH-receptor stimulation produces GH pulses larger than either compound generates alone. Community framing casts GHRP-2 as the more potent alternative to ipamorelin, with appetite stimulation named as the main tradeoff. Since the April 2026 reclassification wave, the stack discussion has mostly continued as if GHRP-2's legal status changed with everything else. It did not. GHRP-2 remains on the Category 2 restricted list. The [FDA's Pharmacy Compounding Advisory Committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) shows the July 23–24 meeting in Silver Spring reviewing BPC-157, KPV, TB-500, MOTS-C, emideltide, semax, and epitalon. GHRP-2 is not in that batch. The next review before February 2027 covers GHK-Cu, Melanotan II, LL-37, and PEG-MGF. GHRP-2 is not in that batch either. The access timeline is genuinely unclear.

What the data says

a diagnostic approval in Japan, controlled human studies, and an evidence file that outranks most compounds that got out in April

The human evidence base for GHRP-2 is more developed than for the majority of peptides that returned to compounding-eligible status in April. One specific reason: GHRP-2 is also known as pralmorelin, the active compound in the Ghrelin Test Kit approved in Japan for diagnostic growth hormone deficiency testing. That is a genuine regulatory review — limited to a diagnostic indication, not a therapeutic one, but it represents the kind of formal agency assessment most research peptides have never been through. [PubMed literature on GHRP-2 and pralmorelin](https://pubmed.ncbi.nlm.nih.gov/?term=GHRP-2+pralmorelin) includes controlled human studies documenting dose-dependent GH release, peak timing, IGF-1 response, and characterization of the appetite effects. A [PMC-published study](https://pmc.ncbi.nlm.nih.gov/articles/PMC2824650/) confirmed that GHRP-2 increases food intake in healthy men at a similar magnitude to ghrelin itself. [ClinicalTrials.gov records for pralmorelin](https://clinicaltrials.gov/search?term=pralmorelin) show registered investigational history. The picture that emerges is a compound with real human-tested pharmacology and a safety signal that regulators are still formally working through — not a compound sitting in the restricted column because it lacks data.

Human-supported — PeptideFactCheck stance

the evidence tier is solid; the access question is what the FDA is still working through

GHRP-2 holds the Human-supported evidence tier on PeptideFactCheck: useful signal, but internet claims may go beyond the data. That tier fits precisely here, and it deserves to be read separately from the current regulatory situation. The Human-supported designation is about evidence quality. The Category 2 restriction is about a formal review process the FDA has not yet completed for this compound. Those are two different things. GHRP-2 is one of the better-evidenced compounds still on the restricted list — better than several compounds that came off it in April. The restriction reflects where it sits in the FDA's multi-step 503A evaluation queue, not a judgment that the underlying pharmacology is unexplored. The July 2026 PCAC meeting covers seven peptides. GHRP-2 is not among them. The next batch review before February 2027 covers five more. GHRP-2 is not among those either. Human-supported means the research is real. Currently restricted means the access story is genuinely unresolved. This site's job is to say both things at the same time.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.